Aimei Health Technology

Aimei Health Technology

Incorporated in 2021 as a Cayman Islands exempted company and headquartered in New York, Aimei Health Technology Co., Ltd. is a special purpose acquisition company led by CEO Juan Carlos Iturregui. The company completed its initial public offering in January 2024, raising $60 million through the sale of 6 million units at $10.00 per unit. Public filings show the trust account is held with Continental Stock Transfer & Trust Company, with the sponsor holding founder shares subject to earn-out provisions. The company's investment mandate centers on the global healthcare industry, with a stated preference for mid-market targets in medical devices, biotechnology, diagnostics, digital health, healthcare services, and pharmaceuticals. The prospectus defines a broad search geography spanning North America, Europe, and Asia-Pacific. The sponsor, Aimei Health Ltd, holds the promote and has agreed not to liquidate founder shares during the initial business combination window. As of the latest public filing, no definitive agreement has been announced. The company's scale is defined by the trust corpus: roughly $60 million in gross proceeds, with standard SPAC mechanics allowing for redemptions at $10.00 per share plus interest prior to any merger vote. The vehicle's timeline runs to January 2026, with the option to extend if shareholders approve. The sole event recorded in the public domain is the January 2024 IPO, which listed on the Nasdaq Global Market under the ticker AFJKU. Team size beyond the named officers and directors is not publicly disclosed. Structurally, Aimei Health Technology operates under the governance constraints of a Cayman Islands blank-check company with a US-listed security. That means the sponsor's economics are back-end loaded entirely on deal completion, and the risk of redemption from arbitrary public float holders is the central dynamic. The target search is specifically healthcare, unlike generalist SPACs, which concentrates sourcing risk but aligns with the management team's disclosed expertise in cross-border healthcare finance (per SEC Filing, 2023).